Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CASP6 | P55212 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 3/20 | 0.43 |
| ▸ | BLM | P54132 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229289 | 1.00 | AURKA (0.46) | AURKAAURKBALDH1A1HSD17B10CYP2C9 | |
| SCHEMBL29384070 | 1.00 | AURKA (0.46) | AURKAAURKBALDH1A1HSD17B10CYP2C9 | |
| SCHEMBL26638157 | 0.98 | AURKA (0.45) | AURKAAURKBALDH1A1HSD17B10CYP2C9 | |
| SCHEMBL592094 | 0.98 | AURKA (0.45) | AURKAAURKBALDH1A1HSD17B10CYP2C9 | |
| SCHEMBL592096 | 0.98 | ALDH1A1 (0.47) | AURKAAURKBALDH1A1HSD17B10CYP2C9 | |
| SCHEMBL22280861 | 0.91 | AURKA (0.41) | AURKAAURKBALDH1A1HSD17B10CYP2C9 | |
| SCHEMBL6818347 | 0.91 | AURKA (0.50) | AURKAAURKBALDH1A1HSD17B10CYP2C9 | |
| SCHEMBL2730921 | 0.91 | AURKA (0.50) | AURKAAURKBALDH1A1HSD17B10CYP2C9 | |
| SCHEMBL3260824 | 0.89 | AURKA (0.49) | AURKAAURKBALDH1A1HSD17B10CYP2C9 | |
| SCHEMBL4402089 | 0.88 | AURKA (0.47) | AURKAAURKBALDH1A1HSD17B10CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 887 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4679077-A1 | OLIGOSACCHARIDE CHAIN-BASED DETECTION REAGENT FOR DETECTING INTESTINAL CANCER, PREPARATION METHOD, AND USE | Xiansida Nanjing Biotechnology Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| US-12510547-B2 | Sample preparation by temperature gradient denaturation and scale-up for deep n-glycomic analysis of serum for capillary electrophoresis and CE-ESI-MS | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2025-12-30 | — | — | US | claimed |
| EP-3737753-B1 | USE OF TRI- AND TETRA-HYDROXYL QUATERNARY AMMONIUM COMPOUNDS AS RESOLVING AGENTS FOR ELECTROPHORESITIC SEPARATIONS | AGILENT TECHNOLOGIES INC (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250290918-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2025-09-18 | — | — | US | claimed |
| EP-3684941-B1 | USE OF POLYAMINES AS RESOLVING AGENTS FOR CAPILLARY ELECTROPHORESIS OF LABELED GLYCANS USING GELS | AGILENT TECHNOLOGIES INC (US) | 2025-05-14 | — | — | EP | claimed |
| US-12286574-B2 | Manipulating hydrophilicity of conventional dye molecules for tracer applications | SAUDI ARABIAN OIL COMPANY (SA) | 2025-04-29 | — | — | US | claimed |
| WO-2025070814-A1 | SUGAR CHAIN PREPARATION METHOD AND SUGAR CHAIN ANALYSIS METHOD | 住友ベークライト株式会社 | 2025-04-03 | — | — | WO | claimed |
| US-12210027-B2 | Glycan sample preparation | BECKMAN COULTER, INC. (US) | 2025-01-28 | — | — | US | claimed |
| WO-2024183385-A1 | OLIGOSACCHARIDE CHAIN-BASED DETECTION REAGENT FOR DETECTING INTESTINAL CANCER, PREPARATION METHOD, AND USE | 先思达（南京）生物科技有限公司 | 2024-09-12 | — | — | WO | claimed |
| WO-2024183386-A1 | OLIGOSACCHARIDE CHAIN-BASED DETECTION REAGENT FOR DETECTING PROSTATE CANCER, PREPARATION METHOD AND USE | 先思达（南京）生物科技有限公司 | 2024-09-12 | — | — | WO | claimed |
| WO-2001092890-A1 | METHOD FOR THE ANALYSIS OF PICOMOLE AMOUNTS OF CARBOHYDRATES | VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (BE) | 2001-12-06 | — | — | WO | claimed |
| US-5964999-A | Methods for profiling oligosaccharides released from glycoproteins | BECKMAN INSTRUMENTS, INC. (US) | 1999-10-12 | — | — | US | claimed |
| EP-0867722-A2 | Method for measuring interaction between sugar and target | TAKARA SHUZO CO. LTD. (JP) | 1998-09-30 | — | — | EP | claimed |
| EP-0763197-A1 | METHOD AND APPARATUS FOR AUTOMATED CARBOHYDRATE MAPPING AND SEQUENCING | PERKIN-ELMER CORPORATION (US) | 1997-03-19 | — | — | EP | claimed |
| WO-1995033989-A1 | METHOD AND APPARATUS FOR AUTOMATED CARBOHYDRATE MAPPING AND SEQUENCING | PERKIN-ELMER CORPORATION (US) | 1995-12-14 | — | — | WO | claimed |
| EP-0397641-B1 | Method for quantitatively determining a chemical parameter of a sample | AVL MEDICAL INSTR AG (CH) | 1995-07-05 | — | — | EP | claimed |
| US-5284558-A | Treating a labelled and charged oligosaccharide with an exoglycosidase to remove the non-reducing monosaccharide; correlating the enzyme specificity with electrophoretic data | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1994-02-08 | — | — | US | claimed |
| US-5232858-A | Selecting substances such that the emission spectrum of the fluorescent overlaps the absorption spectrum of the chromogen; absorption maximum shifted by analyte; fluorescence decay reduced by energy transfer | AVL MEDICAL INSTRUMENTS AG (CH) | 1993-08-03 | — | — | US | claimed |
| WO-1992002816-A1 | ELECTROPHORESIS-BASED SEQUENCING OF OLIGOSACCHARIDES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1992-02-20 | — | — | WO | claimed |
| EP-0397641-A2 | Method for quantitatively determining a chemical parameter of a sample | AVL Medical Instruments AG (CH) | 1990-11-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12510547-B2 | Sample preparation by temperature gradient denaturation and scale-up for deep n-glycomic analysis of serum for capillary electrophoresis and CE-ESI-MS | ANPEP, FUCA2, NPEPPS | AURKA 1772/4885AURKB 1897/4885ALDH1A1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.